国: オーストラリア
言語: 英語
ソース: Department of Health (Therapeutic Goods Administration)
metaraminol tartrate, Quantity: 9.488 mg (Equivalent: metaraminol, Qty 5 mg)
Juno Pharmaceuticals Pty Ltd
Injection, solution
Excipient Ingredients: water for injections; dilute hydrochloric acid; sodium chloride
Intravenous
10
(S4) Prescription Only Medicine
Prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia,Adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. ,It may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.
Visual Identification: A clear, colourless, pyrogen free and sterile solution for injection in a sterile polypropylene prefilled syringe; Container Type: Syringe; Container Material: PP; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2019-03-07
Metaraminol Juno 1 METARAMINOL JUNO CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING METARAMINOL JUNO? Metaraminol Juno contains the active ingredient metaraminol tartrate. Metaraminol Juno is used to increase your blood pressure which can drop during spinal anaesthesia or can drop as a reaction to medications or surgical complications. For more information, see Section 1. Why am I using Metaraminol Juno? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE METARAMINOL JUNO? Do not use if you have ever had an allergic reaction to Metaraminol Juno or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use Metaraminol Juno? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with Metaraminol Juno and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE METARAMINOL JUNO? • Metaraminol Juno must only be given by a doctor or nurse. • Metaraminol Juno is administered in a hospital as an injection into a vein or diluted before use and given with fluids into a vein. • Your doctor will decide what dose of Metaraminol Juno you will receive and how long you will receive it for. This depends on your medical condition and other factors, such as your weight. More instructions can be found in Section 4. How do I use Metaraminol Juno? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING METARAMINOL JUNO? THINGS YOU SHOULD DO • Always follow your doctor's instructions carefully. • Your doctor or nurse will monitor your blood pressure. • Remind any doctor, dentist or pharmacist you visit that you are using Metaraminol Juno. DRIVING OR USING MACHINES • 完全なドキュメントを読む
Australian Product Information METARAMINOL JUNO SOLUTION FOR INJECTION _ _ _ (METARAMINOL (AS TARTRATE)) _ _ _ PRODUCT INFORMATION 1 NAME OF THE MEDICINE Metaraminol tartrate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Metaraminol tartrate is a white, crystalline powder, which is freely soluble in water, slightly soluble in alcohol, and practically insoluble in chloroform and in ether. Each mL of Metaraminol Juno solution for injection contains metaraminol (as tartrate) 0.5 mg, sodium chloride 9 mg, hydrochloric acid and water for injections to 1 mL. For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS. 3. PHARMACEUTICAL FORM Metaraminol (as tartrate) 5mg/10mL injection pre-filled syringe Metaraminol (as tartrate) 2.5mg/5mL injection pre-filled syringe 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia • Adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. • It may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia. 4.2 DOSE AND METHOD OF ADMINISTRATION Metaraminol Juno injection is for intravenous administration only (injection) and should be used in one patient on one occasion only. It contains no antimicrobial preservative. Unused solution should be discarded. Because the maximum effect is not immediately apparent, at least ten minutes should elapse before increasing the dosage. As the effect tapers off when the vasopressor is discontinued, the patient should be carefully observed so that therapy can be reinitiated promptly if the blood pressure falls too rapidly. Patients with coexistent shock and acidosis may show a poor response to vasopressors. Established methods of shock management, such as blood or fluid replacement when indicated, and other measures directed to the specific cause of the shock also should be used. Australian Pro 完全なドキュメントを読む